Abstract
Kidney cancer is among the most common adult malignancies [1]. The majority of cases will be detected and managed by urologists; however, in 2–3 % of all cases of RCC, there is a major inherited predisposition. These complex cases may require additional input from nephrologists and clinical geneticists [2]. The presence of characteristic tumours or extra-renal signs may point to a diagnosis of a specific RCC susceptibility syndrome. It is important to recognise that renal cancer is only one aspect of these complex multisystem disorders and that optimal patient care requires long-term follow-up and the close liaison of a broad multi-specialty team.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Cancel Research UK. Kidney cancer – UK incidence statistics. 2011. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/incidence/
Maher ER. Genetics of familial renal cancers. Nephron Exp Nephrol. 2011;118(1):e21–6.
Melmon KL, Rosen SW. Lindau's disease. Review of the literature and study of a large kindred. Am J Med. 1964;36:595–617.
Maher ER. Von Hippel-Lindau disease. Curr Mol Med. 2004;4(8):833–42.
Latif F, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20.
Nickerson ML, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726–34.
Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402.
Linehan WM, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329–43.
Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145–73.
Nordstrom-O'Brien M, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–37.
Neumann HPH, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.
Lonser RR, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.
Walther MM, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161(5):1475–9.
Herring JC, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol. 2001;165(3):777–81.
Goldfarb DA, et al. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation. 1997;64(12):1726–9.
Lee S, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;8(2):155–67.
Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7(5):277–85.
Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56.
Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15–20.
Yates JR, et al. The tuberous sclerosis 2000 study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child. 2011;96(11):1020–5.
Siroky BJ, Czyzyk-Krzeska MF, Bissler JJ. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol. 2009;5(3):143–56.
Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13(12):624–8.
Menko FH, et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol. 2009;10(12):1199–206.
Nickerson ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2(2):157–64.
Toro JR, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45(6):321–31.
Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer. 2011;10(2):397–411.
Alam NA, et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol. 2005;141(2):199–206.
Smit DL, et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet. 2011;79(1):49–59.
Woodward ER, et al. Population-based survey of cancer risks in chromosome 3 translocation carriers. Genes Chromosomes Cancer. 2010;49(1):52–8.
Schmidt L, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73.
Baysal BE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848–51.
Ricketts CJ, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Connor, T.M.F., Maxwell, P.H. (2014). Inherited Renal Tumour Syndromes. In: Harber, M. (eds) Practical Nephrology. Springer, London. https://doi.org/10.1007/978-1-4471-5547-8_40
Download citation
DOI: https://doi.org/10.1007/978-1-4471-5547-8_40
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-5546-1
Online ISBN: 978-1-4471-5547-8
eBook Packages: MedicineMedicine (R0)